Oragenics Inc (OGEN) - News Archive

Oragenics, Inc.: Pioneering Neurological Therapeutics Amidst a New Strategic VisionIn the rapidly evolving landscape of biotechnology, few companies have displayed the agility and foresight necessary to adapt and innova...

Oragenics, Inc. Takes Strategic Steps: Preferred Shares Conversion and Successful Public Offerings Sarasota, FL September 5, 2024: Oragenics, Inc. (NYSE American: OGEN) continues to make significant strides in its missi...

Oragenics, Inc. Makes Significant Progress in Concussion Drug Development Ahead of Phase II Trials Oragenics, Inc. (NYSE American: OGEN), a biopharmaceutical company based in Sarasota, Florida, has made significant stri...

In an era where neuroscience innovations continually redefine the boundaries of medical science, Oragenics Inc. a nascent trailblazer headquartered in Sarasota, Florida, has marked a pivotal milestone in its quest to re...

IntroductionnnOn September 5, 2024, Oragenics, Inc. (NYSE American: OGEN), an innovative biotech company specializing in intranasal pharmaceuticals for treating neurological disorders, announced the successful closing o...

In recent developments within the biotech industry, Oragenics Inc. has made strides in its commitment to addressing concussions, a significant public health issue. The company has announced the completion of spray-dry d...

Sarasota, Fla. - August 16, 2024 Oragenics, Inc. (NYSE American: OGEN), a pioneering biopharmaceutical company focused on developing innovative intranasal treatments for neurological disorders, has provided notable upda...

In this most propitious season of scientific endeavor, we find ourselves adorned with delightful tidings from the distinguished halls of Oragenics, Inc. The esteemed purveyors of pharmaceutical innovation have recently...

Oragenics, a renowned biopharmaceutical company, has recently developed an innovative automated intranasal device designed to provide initial treatment for concussed patients. This breakthrough technology is expected to...

SARASOTA, Fla., June 26, 2024 - Oragenics, Inc. (NYSE American: OGEN), a leading company specializing in the development of innovative intranasal pharmaceuticals for the treatment of neurological disorders, has announce...

Oragenics, Inc., a prominent player in the development of intranasal pharmaceuticals for neurological disorders, has recently announced a public offering to raise funds for its ongoing operations. This move comes at a t...

Oragenics, Inc. Announces Proposed Public Offering to Fund Development of Intranasal Pharmaceuticals for Neurological DisordersOragenics, Inc. (NYSE: OGEN), a company specializing in the development of unique intranasal...

Oragenics, Inc. Advances Phase II Concussion Clinical Trial for Intranasal Pharmaceutical ONP-002 SARASOTA, Fla., May 16, 2024 In an era marked by rapid advancements in medicinal technologies, Oragenics, Inc. (NYSE Amer...

Sophisticated Oragenics Partners with Avance Clinical for Phase II Concussion Trial in AustraliaSARASOTA, Fla., May 07, 2024 - Oragenics, Inc. (NYSE American: OGEN), a pioneering company in the development of innovative...